The European Medicines Agency’s said Thursday that it has completed a safety review and concluded that evidence "does not support any increased risk of cancer" in patients taking angiotensin-receptor blockers (ARBs). The FDA reached a similar conclusion earlier this year on the drugs.
A review was launched by the agency’s Committee for Medicinal Products for Human Use (CHMP) last June after a meta-analysis showed a small increased risk of new cancers with ARBs compared with placebo and other heart therapies. After examining the study, the CHMP "found that the evidence from the meta-analysis was weak," and suggested that there were "several problems with the quality of the data, specifically that patients in the trials were not followed up for long enough to clearly establish a link between ARBs."
The committee also reviewed data from other studies and meta-analyses, and concluded that "the results did not show an increased risk of cancer with ARBs."